Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | F2 | P00734 | 9/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.31 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19962027 | 0.94 | KMT2A (0.33) | KMT2AF2 | |
| SCHEMBL18180358 | 0.88 | ALDH1A1 (0.41) | KMT2AF2MAPTMEN1 | |
| SCHEMBL18180421 | 0.88 | ALDH1A1 (0.41) | KMT2AF2MAPTMEN1 | |
| SCHEMBL18179904 | 0.87 | TAS1R3 (0.38) | KMT2APSMB5MEN1 | |
| SCHEMBL19969339 | 0.83 | SYK (0.34) | — | |
| SCHEMBL19962082 | 0.83 | SYK (0.34) | — | |
| SCHEMBL19962015 | 0.83 | ALDH1A1 (0.37) | KMT2AF2MAPTMEN1 | |
| SCHEMBL19962064 | 0.82 | PIN1 (0.36) | KMT2APSMB5MEN1 | |
| SCHEMBL19962152 | 0.82 | PDE10A (0.34) | KMT2AMAPTMEN1 | |
| SCHEMBL19969220 | 0.81 | PDE10A (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180072997-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072997-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR2H, POLR2E | KMT2A 3986/4885F2 3297/4885PSMB5 2506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.